Namyang Dairy is in trouble after a number of furious investors have called for a boycott. They urged the consumers to stop buying the company’s products.
Namyang’s COVID-19 claim
The root cause of this action from the investors was Namyang Dairy’s claim that its Bulgaris yogurt drink can help fight the symptoms of COVID-19. Last week, the South Korean food and dairy company said that its stock price increased by more than eight percent on April 13 and continued to go up to over 28% the next day.
At that time, it was reported that Namyang’s share surge was caused by the consumers’ rush to buy its Bulgaris yogurt after it released a statement saying that the product can prevent COVID-19. However, health officials are questioning the company’s claims and suggested that they are false and have no scientific basis.
The controversial claim was announced during a symposium hosted by the Korea Research & Institute of BioMedical last week. At the event, Namyang’s internal research institute presented the results of its research on Yogurt drink called Bulgaris, as per The Korea Herald.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Company’s representative, Park Jong Su, said at the symposium. “Our experiments showed that Bulgaris helped remove the influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
S. Korea’s food and drug ministry reacts
The experts from the Ministry of Food and Drug Safety and Korea Disease Control and Prevention Agency immediately questioned Namyang’s statements about its Bulgaris yogurt. They are asking about the effectiveness claim against COVID-19 and they concluded that the dairy firm exaggerated the research results that it released in the previous symposium.
The Korea Times reported that because of this, the investors are now taking action against Namyang. They are using social media to ask the public to join in their calls to boycott the company’s products. Apparently, they are angry not just due to the coronavirus statements but also because they believe Namyang lied to manipulate the stock price.
Meanwhile, amid the backlash from the public and health experts, Namyang Dairy issued an apology for the confusion. "We apologize to our customers for causing misunderstanding with our research results,” a company official stated. “The test was not based on human testing, but at the cellular stage, from which we couldn't have concluded its effectiveness against COVID-19."


Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline
Global Markets React as Dollar Surges, Swiss Franc Rallies After U.S.-Israel Strike on Iran
Qantas Shares Plunge 10% as Iran Strikes Send Oil Prices Soaring and Disrupt Global Flights
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets
AWS Data Center in UAE Hit by Fire After Objects Strike Facility Amid Regional Tensions
Asian Currencies Slide as US-Israel Strikes on Iran Trigger Oil Surge and Risk-Off Rally
Lynas Rare Earths Shares Surge 7% After Malaysia Renews Processing Plant Licence for 10 Years
Stock Market Movers: Dell, Block, Duolingo, Zscaler, CoreWeave, Autodesk, Rocket, MARA
MOEX Russia Index Hits 3-Month High as Energy Stocks Lead Gains
Panama Investigates CK Hutchison’s Port Unit After Court Voids Canal Contracts
Rachel Reeves Signals Fiscal Discipline in UK Budget Update Amid Middle East Tensions 



